OncoTargets and Therapy

Código QR

OncoTargets and Therapy

Guardado en:

Detalles Bibliográficos
Formato:	journal
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	oncology cancer therapeutic agents Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/toc/1178-6930
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

OncoTargets and therapy
Publicado: (2008)

Breast Cancer: Targets and Therapy
Publicado: (2010)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Dana S. Neel, et al.
Publicado: (2017)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Jin Yuan MD, et al.
Publicado: (2021)

MET targeted therapy for lung cancer: clinical development and future directions
por: Feng Y, et al.
Publicado: (2012)

Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
por: Razan Alzeibak, et al.
Publicado: (2021)

Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Publicado: (2021)

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
por: Steven P. Angus, et al.
Publicado: (2021)

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
por: Istvan Petak, et al.
Publicado: (2021)

Correction to: ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma
por: Weipu Mao, et al.
Publicado: (2021)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Pascale Lejeune, et al.
Publicado: (2021)

Avaliação do Risco Nutricional em Pacientes Onco-Hematológicos Hospitalizados
por: Brena Custódio Rodrigues, et al.
Publicado: (2019)

Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
por: Jason J. Zoeller, et al.
Publicado: (2017)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: Federica Cappuccini, et al.
Publicado: (2021)

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
por: Vladimir Lazar, et al.
Publicado: (2021)

Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells
por: Chatterjee S, et al.
Publicado: (2015)

Production of Long-Acting CNGRC–CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment
por: Layla Al-mansoori, et al.
Publicado: (2021)

Targeting the duality of cancer
por: Jack L. Arbiser, et al.
Publicado: (2017)

Targeted inhibition in tumors with ALK dependency
por: Kwak EL, et al.
Publicado: (2013)

Differentiation therapy for myeloid malignancies: beyond cytotoxicity
por: Ryan J. Stubbins, et al.
Publicado: (2021)

Emerging targeted combinations in the management of breast cancer
por: Lee RJ, et al.
Publicado: (2013)

Targeting &gamma;-secretase in breast cancer
por: Han J, et al.
Publicado: (2012)

EBV based cancer prevention and therapy in nasopharyngeal carcinoma
por: Ya Cao
Publicado: (2017)

Microbiome dysbiosis in lung cancer: from composition to therapy
por: Ning-Ning Liu, et al.
Publicado: (2020)

Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling
por: Feng Liu, et al.
Publicado: (2017)

Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Jessica S. Donington, MD
Publicado: (2021)

Decreased risk of breast cancer associated with oral bisphosphonate therapy
por: Mathew A, et al.
Publicado: (2012)

Inhibiting breast cancer by targeting the thromboxane A2 pathway
por: Haitao Li, et al.
Publicado: (2017)

Revisiting the IGF-1R as a breast cancer target
por: Roudy Chiminch Ekyalongo, et al.
Publicado: (2017)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto RA, et al.
Publicado: (2015)

Traditional Chinese Medicine Therapy for Esophageal Cancer: A Literature Review
por: Luchang Cao MB, et al.
Publicado: (2021)

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
por: Michael Bitzer, et al.
Publicado: (2021)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga N, et al.
Publicado: (2015)

Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma
por: Matthew A. Wall, et al.
Publicado: (2021)

Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
por: Chan VTC, et al.
Publicado: (2011)

Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy
por: Yael Artzy-Randrup, et al.
Publicado: (2021)

Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression
por: Wei He, et al.
Publicado: (2017)

Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter
por: Goldfinger LE, et al.
Publicado: (2013)

Enhanced radiation response in radioresistant MCF-7 cells by targeting peroxiredoxin II
por: Diaz AJG, et al.
Publicado: (2013)